Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Jul
16
Today In Oncology
Virtual Sustained Counseling and Tobacco Treatment Improve Quit Rates for Patients With Cancer in Community Settings
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
Digital Check-ins May Improve Outcomes in Patients Undergoing Treatment for Advanced Cancer
How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?
ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo